Lofexidine vs Buprenorphine: Long-Term Effectiveness Comparison for Opioid Withdrawal Relief

Study on Medications for Opiate Withdrawal Relief

Background on Opiate Dependence

Opiate dependence is a significant global health issue, with more than 11 million heroin users worldwide. Opiates, which include illicit substances like heroin and prescription painkillers such as codeine, morphine, and oxycodone, have sedative or narcotic effects. Addressing opiate dependence involves three critical phases: stabilization, detoxification, and maintenance of abstinence. Success in overcoming dependence largely depends on effective treatment throughout these stages. The detoxification phase is often the most challenging, as withdrawal symptoms can hinder completion and lead to lower long-term abstinence rates.

Comparative Study of Lofexidine and Buprenorphine

To explore potential improvements in managing withdrawal symptoms, a recent study by Law and colleagues, published in the Journal of Psychopharmacology, compared lofexidine and buprenorphine as treatments for opiate-dependent individuals. The study aimed to assess which medication could better assist clients in completing detoxification.

The trial involved 80 opiate-dependent participants aged 16 to 65, all of whom had been using prescribed or illicit opiates (equivalent to a quarter gram of heroin intravenously) for less than three years. Participants were randomly assigned to one of two treatment programs over a short-term period of 18 months. These programs included induction and stabilization on methadone or buprenorphine/naloxone, followed by detoxification, where those on methadone received lofexidine. Urine drug screens and withdrawal and cravings questionnaires were administered throughout the study.

Effectiveness of Treatment Options

Both lofexidine and buprenorphine/naloxone have proven effective for managing opiate withdrawal symptoms, albeit through different mechanisms. This study was the first to compare these treatments directly during detoxification in opiate-dependent individuals.

Findings from the Study

Results revealed no significant differences in urine drug screens or dropout rates among the trial phases. During the induction and stabilization phase, participants on the buprenorphine/naloxone regimen experienced slower subsidence of withdrawal symptoms and higher cravings compared to those on methadone. However, during detoxification, individuals receiving methadone and lofexidine reported more severe withdrawal symptoms, which peaked earlier than in the buprenorphine/naloxone group.

Both treatment regimens resulted in similar proportions of negative urine samples during detoxification, with 44 participants successfully completing this phase (21 from the buprenorphine/naloxone group and 23 from the methadone/lofexidine group).

Conclusion: Comparing Comfort and Speed of Detoxification

Overall, both treatment options yielded comparable results in terms of reducing illicit drug use, alleviating withdrawal symptoms, and minimizing dropout rates among low-dose opiate-dependent individuals. While buprenorphine/naloxone may provide a more comfortable detoxification experience, it does so at a slower pace. Conversely, lofexidine following methadone offers a more rapid detoxification but may lead to increased discomfort.

Reference

Law FD, Diaper AM, Melichar JK, Coulton S, Nutt DJ, Myles JS. Buprenorphine/naloxone versus methadone and lofexidine in community stabilization and detoxification: A randomized controlled trial of low dose short-term opiate-dependent individuals. J Psychopharmacol. 2017 Aug;31(8):1046-1055. doi: 10.1177/0269881117711710.